387 related articles for article (PubMed ID: 20035570)
1. Arsenic-induced carcinogenesis--oxidative stress as a possible mode of action and future research needs for more biologically based risk assessment.
Kitchin KT; Conolly R
Chem Res Toxicol; 2010 Feb; 23(2):327-35. PubMed ID: 20035570
[TBL] [Abstract][Full Text] [Related]
2. Research toward the development of a biologically based dose response assessment for inorganic arsenic carcinogenicity: a progress report.
Clewell HJ; Thomas RS; Gentry PR; Crump KS; Kenyon EM; El-Masri HA; Yager JW
Toxicol Appl Pharmacol; 2007 Aug; 222(3):388-98. PubMed ID: 17499324
[TBL] [Abstract][Full Text] [Related]
3. Recent advances in arsenic carcinogenesis: modes of action, animal model systems, and methylated arsenic metabolites.
Kitchin KT
Toxicol Appl Pharmacol; 2001 May; 172(3):249-61. PubMed ID: 11312654
[TBL] [Abstract][Full Text] [Related]
4. Arsenic, mode of action at biologically plausible low doses: what are the implications for low dose cancer risk?
Snow ET; Sykora P; Durham TR; Klein CB
Toxicol Appl Pharmacol; 2005 Sep; 207(2 Suppl):557-64. PubMed ID: 15996700
[TBL] [Abstract][Full Text] [Related]
5. Chloroform mode of action: implications for cancer risk assessment.
Golden RJ; Holm SE; Robinson DE; Julkunen PH; Reese EA
Regul Toxicol Pharmacol; 1997 Oct; 26(2):142-55. PubMed ID: 9356278
[TBL] [Abstract][Full Text] [Related]
6. Cancer risk assessment for 1,3-butadiene: data integration opportunities.
Preston RJ
Chem Biol Interact; 2007 Mar; 166(1-3):150-5. PubMed ID: 16647696
[TBL] [Abstract][Full Text] [Related]
7. Risk assessment of arsenic-induced internal cancer at long-term low dose exposure.
Liao CM; Shen HH; Chen CL; Hsu LI; Lin TL; Chen SC; Chen CJ
J Hazard Mater; 2009 Jun; 165(1-3):652-63. PubMed ID: 19062162
[TBL] [Abstract][Full Text] [Related]
8. Development of a quantitative model incorporating key events in a hepatotoxic mode of action to predict tumor incidence.
Luke NS; Sams R; DeVito MJ; Conolly RB; El-Masri HA
Toxicol Sci; 2010 May; 115(1):253-66. PubMed ID: 20106946
[TBL] [Abstract][Full Text] [Related]
9. Arsenic-induced bladder cancer in an animal model.
Cohen SM; Ohnishi T; Arnold LL; Le XC
Toxicol Appl Pharmacol; 2007 Aug; 222(3):258-63. PubMed ID: 17109909
[TBL] [Abstract][Full Text] [Related]
10. Research approaches to address uncertainties in the risk assessment of arsenic in drinking water.
Hughes MF; Kenyon EM; Kitchin KT
Toxicol Appl Pharmacol; 2007 Aug; 222(3):399-404. PubMed ID: 17379267
[TBL] [Abstract][Full Text] [Related]
11. Arsenic carcinogenesis in the skin.
Yu HS; Liao WT; Chai CY
J Biomed Sci; 2006 Sep; 13(5):657-66. PubMed ID: 16807664
[TBL] [Abstract][Full Text] [Related]
12. How can biologically-based modeling of arsenic kinetics and dynamics inform the risk assessment process? - A workshop review.
Kenyon EM; Klimecki WT; El-Masri H; Conolly RB; Clewell HJ; Beck BD
Toxicol Appl Pharmacol; 2008 Nov; 232(3):359-68. PubMed ID: 18687352
[TBL] [Abstract][Full Text] [Related]
13. Oral exposure to inorganic arsenic: evaluation of its carcinogenic and non-carcinogenic effects.
Schuhmacher-Wolz U; Dieter HH; Klein D; Schneider K
Crit Rev Toxicol; 2009; 39(4):271-98. PubMed ID: 19235533
[TBL] [Abstract][Full Text] [Related]
14. Bayesian estimation of pharmacokinetic and pharmacodynamic parameters in a mode-of-action-based cancer risk assessment for chloroform.
Liao KH; Tan YM; Conolly RB; Borghoff SJ; Gargas ML; Andersen ME; Clewell HJ
Risk Anal; 2007 Dec; 27(6):1535-51. PubMed ID: 18093051
[TBL] [Abstract][Full Text] [Related]
15. Arsenic toxicity at low doses: epidemiological and mode of action considerations.
Schoen A; Beck B; Sharma R; Dubé E
Toxicol Appl Pharmacol; 2004 Aug; 198(3):253-67. PubMed ID: 15276404
[TBL] [Abstract][Full Text] [Related]
16. An adjustment factor for mode-of-action uncertainty with dual-mode carcinogens: the case of naphthalene-induced nasal tumors in rats.
Bogen KT
Risk Anal; 2008 Aug; 28(4):1033-51. PubMed ID: 18564993
[TBL] [Abstract][Full Text] [Related]
17. The impact of recent advances in research on arsenic cancer risk assessment.
Gentry PR; Clewell HJ; Greene TB; Franzen AC; Yager JW
Regul Toxicol Pharmacol; 2014 Jun; 69(1):91-104. PubMed ID: 24534001
[TBL] [Abstract][Full Text] [Related]
18. Research strategy for developing key information on bromate's mode of action.
Bull RJ; Cottruvo JA
Toxicology; 2006 Apr; 221(2-3):135-44. PubMed ID: 16298034
[TBL] [Abstract][Full Text] [Related]
19. An evaluation of the mode of action framework for mutagenic carcinogens case study: Cyclophosphamide.
McCarroll N; Keshava N; Cimino M; Chu M; Dearfield K; Keshava C; Kligerman A; Owen R; Protzel A; Putzrath R; Schoeny R
Environ Mol Mutagen; 2008 Mar; 49(2):117-31. PubMed ID: 18240158
[TBL] [Abstract][Full Text] [Related]
20. Analysis of in vivo mutation data can inform cancer risk assessment.
Moore MM; Heflich RH; Haber LT; Allen BC; Shipp AM; Kodell RL
Regul Toxicol Pharmacol; 2008 Jul; 51(2):151-61. PubMed ID: 18321622
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
